BioCentury
ARTICLE | Finance

Gossamer’s war chest

Why Gossamer has been able to raise $330 million since January

July 26, 2018 8:56 PM UTC

Gossamer Bio Inc. has built a huge war chest from investors lured by the prospect of near-term milestones, a plan for rapid pipeline growth and a winning management team from Receptos Inc. With Monday’s $230 million series B round, the inflammation and immunology company has amassed $330 million since its January launch and hasn’t ruled out the possibility of a near-term IPO.

Hillhouse Capital led the untranched round, joined by fellow new investors Polaris Partners, Abu Dhabi Investment Authority, Invus and The Baupost Group and existing investors Arch Venture Partners and Omega Funds. ...